Drug intelligence / Profile preview

2039125 03 + sunscreen

Development stage: Unknown
Lead developer: Galderma
Modality: Small Molecules
Administration: Topical

Overview

2039125 03 + sunscreen is a combination product investigated by Galderma for the treatment of actinic keratosis. The product consists of a specific formulation identified by the code 2039125 03, which is used in conjunction with a sunscreen. Actinic keratosis is a precancerous skin condition caused by chronic exposure to ultraviolet (UV) radiation, and the inclusion of sunscreen in the regimen is intended to provide photoprotection while the active therapeutic component addresses existing lesions. Clinical trials have evaluated the efficacy and safety of this combination compared to sunscreen alone or other vehicles to determine its impact on lesion clearance and prevention of progression to squamous cell carcinoma.

Other names: 2039125 03 plus sunscreen

Beyond the preview

Go deeper on 2039125 03 + sunscreen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2039125 03 + sunscreen.

Explore the full profile